Group 1 - The core idea of the news is the launch of ten innovative policy reform pilot projects in Gansu Province aimed at stimulating innovation and creating a better technological innovation ecosystem to support the establishment of a regional technology innovation and transformation base [2][6] - The Gansu Provincial Innovation Policy Reform Pilot Work aims to enhance the effectiveness of technological breakthroughs by organizing collaboration among enterprises, universities, and research institutions [2][4] - The Gansu High-tech Zone has developed a model focusing on collaborative development in the biopharmaceutical industry, targeting areas such as gene and cell therapy, AI+pharmaceuticals, and new vaccine development [2][3] Group 2 - The Gansu Province aims to achieve a total biopharmaceutical output value exceeding 30 billion yuan within a year, with plans to develop 3-5 generic drugs or biological products and 2-3 innovative drugs [3] - A technology investment conference was held, featuring major scientific contributions and technology demands from various sectors, including new energy, new materials, and biomedicine [4] - The Gansu Province has successfully signed contracts for 30 major technology resource introduction projects, demonstrating active engagement in technology investment and collaboration [4] Group 3 - The pilot reform of talent evaluation in Gansu Province focuses on establishing a new evaluation system based on innovation capability, effectiveness, and contribution [5] - The Gansu Provincial Science and Technology Information Research Institute has categorized scientific talents into four types, creating tailored growth paths to promote meritocracy [5] - The pilot program has shown significant results, boosting confidence in further reforms and the expansion of pilot projects across the province [6]

Core Viewpoint - Qizheng Tibetan Medicine (002287) announced that its convertible bond, "Qizheng Convertible Bond," will cease trading after the afternoon session on August 28, with the last conversion day on September 2 [1] Summary by Relevant Sections - **Trading Status** - "Qizheng Convertible Bond" will stop trading after the close of the market on August 28, leaving only half a trading day for transactions [1] - There are only three trading days left before the bond stops conversion and is redeemed after the close on September 2 [1] - **Conversion Details** - Investors holding "Qizheng Convertible Bond" can still convert their bonds until the market closes on September 2 [1]

| 证券代码：002287 | 证券简称：奇正藏药 | 公告编号：2025-080 | | --- | --- | --- | | 债券代码：128133 | 债券简称：奇正转债 | | 西藏奇正藏药股份有限公司 关于"奇正转债"即将停止交易暨最后半个交易日 的重要提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、最后交易日：2025年8月28日 截至本公告披露时，"奇正转债"距离停止交易仅剩最后半个交易日（2025 年8月28日下午交易时段），本日"奇正转债"简称已变更为"Z正转债"。2025 年8月28日收市后"奇正转债"将停止交易。 2、最后转股日：2025年9月2日 2025年9月2日是"奇正转债"最后一个转股日，当日收市前，持有"奇正转 债"的投资者仍可进行转股；2025年9月2日收市后，未转股的"奇正转债"将停 止转股。 3、截至2025年8月28日收市后，距离"奇正转债"停止转股并赎回仅剩3个 交易日。本公司特提醒投资者仔细阅读本公告内容，关注相关风险，谨慎交易"奇 正转债"。 特别提示： 1、"奇正转债"赎回价格： ...

Core Viewpoint - Qizheng Tibetan Medicine is leveraging its traditional Tibetan medicine expertise to innovate and expand in modern healthcare, aiming for global promotion and integration of Tibetan medicine with modern medical practices [2][6][7] Group 1: Company Overview - Qizheng Tibetan Medicine is the only publicly listed company in China focused on Tibetan medicine, with a history of 30 years in the industry [2] - The company’s flagship product, "Pain Relief Plaster," has become a leading brand in the domestic musculoskeletal pain market, showcasing the successful modernization of Tibetan medicine [4] Group 2: Product Development and Innovation - The company is expanding its product pipeline beyond pain management to include respiratory, neurological, and gynecological fields, addressing the rising prevalence of chronic diseases due to an aging population [5] - The "Pain Relief Plaster" utilizes advanced low-temperature freeze-drying technology to preserve the active ingredients of medicinal materials, enhancing its clinical value [4] Group 3: Research and Clinical Applications - Qizheng has initiated multiple clinical collaborations, demonstrating the effectiveness of Tibetan medicine in reducing recurrence rates and side effects in treatments like chronic pelvic inflammatory disease and cancer support [3] - The company has established a comprehensive research and development system that integrates classic exploration, pharmacological research, and dosage form innovation [3] Group 4: Strategic Vision and Goals - The company aims to double its business in the pain relief sector within five years and establish a 10 billion yuan full industry chain in Tibetan medicine within ten years, aspiring to become a globally influential Tibetan medicine health industry group in thirty years [6] - The strategic framework includes health care, cultural heritage, technological innovation, resource protection, and employee development [6] Group 5: Commitment to Traditional Medicine - Qizheng emphasizes the importance of preserving traditional Tibetan medicine while modernizing and internationalizing it, ensuring that all products are based on Tibetan medical texts and validated through modern clinical trials [7] - The company is committed to creating value for investors by promoting the development of traditional Tibetan medicine through modernization and standardization [7]

Group 1 - The company announced the early redemption of "Qizheng Convertible Bonds" and the upcoming cessation of trading [1] - The last trading day for the bonds is set for August 28, 2025, and the last conversion day is September 2, 2025 [1] - The redemption price is 101.701 yuan per bond, including accrued interest, with the redemption date on September 3, 2025 [1] Group 2 - The board of directors decided to exercise the early redemption rights due to the company's stock price triggering conditional redemption clauses [1] - Investors are reminded to pay attention to the conversion deadline to avoid potential losses, especially those with pledged or frozen shares [1]

| 证券代码：002287 | 证券简称：奇正藏药 | 公告编号：2025-078 | | --- | --- | --- | | 债券代码：128133 | 债券简称：奇正转债 | | 西藏奇正藏药股份有限公司 关于提前赎回"奇正转债"实施暨即将停止交易的重要提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、最后交易日：2025年8月28日 2025年8月28日是"奇正转债"最后一个交易日，当日"奇正转债"简称为 "Z正转债"；2025年8月28日收市后"奇正转债"将停止交易。 2、最后转股日：2025年9月2日 2025年9月2日是"奇正转债"最后一个转股日，当日收市前，持有"奇正转 债"的投资者仍可进行转股；2025年9月2日收市后，未转股的"奇正转债"将停 止转股。 3、截至2025年8月26日收市后，距离"奇正转债"停止交易仅剩2个交易日， 距离"奇正转债"停止转股并赎回仅剩5个交易日。本公司特提醒投资者仔细阅 读本公告内容，关注相关风险，谨慎交易"奇正转债"。 特别提示： 1、"奇正转债"赎回价格：101.701元/张 ...

Core Viewpoint - The company has decided to exercise the early redemption of its convertible bonds "奇正转债" due to current market conditions and its own situation, with the redemption process set to take place shortly [2][6]. Group 1: Convertible Bond Details - The company issued 8 million convertible bonds at a face value of 100 RMB each, totaling 800 million RMB, which began trading on October 27, 2020 [2]. - The bond's conversion period started on March 29, 2021, and will end on September 21, 2026 [2]. - The current redemption price for "奇正转债" is set at 101.701 RMB per bond, which includes accrued interest [8]. Group 2: Redemption Conditions - The company has the right to redeem the bonds if the stock price remains above 130% of the conversion price for at least 15 trading days within a 30-day period [6]. - The redemption will occur on September 2, 2025, after which the bonds will be delisted from the Shenzhen Stock Exchange [9]. Group 3: Shareholder Transactions - The company's major shareholders, including the actual controller and those holding over 5% of shares, did not engage in any transactions involving "奇正转债" in the six months leading up to the redemption conditions being met [9]. Group 4: Redemption Process - Bondholders must submit their conversion requests through the securities company that holds their bonds, and the conversion must be in whole shares [10]. - The redemption funds will be credited to the bondholders' accounts on September 10, 2025 [9].

Financial Performance - The company reported an impressive operating cash flow of 0.92 CNY per share, reflecting a year-on-year increase of 991.52% [2] - The net cash flow from operating activities increased by 993.71% due to optimized cash flow management and accelerated discounting of receivables [2][5] Sales and Marketing Strategy - The company has established a strong presence in both B2C and O2O channels, achieving rapid growth by collaborating with major platforms and expanding its online medical resources [3] - The O2O strategy focuses on differentiated operations based on consumer needs, enhancing exposure and conversion rates through targeted marketing [3] - The company’s pain relief patches have outperformed the industry growth rate due to their dual efficacy in pain relief and anti-inflammation [4] Research and Development - The company is concentrating its R&D efforts on key therapeutic areas such as external pain relief, respiratory, and neurological treatments, with a focus on unmet clinical needs [4][6] - The new drug "Xiaoer Relixin Granules" has received clinical trial approval, enhancing the pediatric product pipeline [5] - R&D investment reached 48.65 million CNY in the first half of the year, a 3.31% increase year-on-year, with a R&D expense ratio of 5.6%, below the industry average [6] Market Position and Competitive Advantage - The company has established itself as a leading brand in the Tibetan medicine market, particularly in external pain relief [6] - The competitive landscape has intensified due to increased demand for topical anti-inflammatory products, but the company maintains a unique advantage with its multi-target Tibetan medicine formulations [4] - The company’s strategic focus on brand recognition and product differentiation supports its market leadership [6] Future Outlook - The company plans to enhance its cash flow management through improved receivables management and expanded financing channels to support business growth and R&D investments [5] - The ongoing construction of the pharmaceutical industrial base is on track, with production licenses being obtained for various formulations [4]

| 证券代码：002287 | 证券简称：奇正藏药 | 公告编号：2025-077 | | --- | --- | --- | | 债券代码：128133 | 债券简称：奇正转债 | | 西藏奇正藏药股份有限公司 关于提前赎回"奇正转债"实施暨即将停止交易的重要提示性公告 3、截至2025年8月25日收市后，距离"奇正转债"停止交易仅剩3个交易日， 距离"奇正转债"停止转股并赎回仅剩6个交易日。本公司特提醒投资者仔细阅 读本公告内容，关注相关风险，谨慎交易"奇正转债"。 特别提示： 重要内容提示： 1、最后交易日：2025年8月28日 2025年8月28日是"奇正转债"最后一个交易日，当日"奇正转债"简称为 "Z正转债"；2025年8月28日收市后"奇正转债"将停止交易。 2、最后转股日：2025年9月2日 2025年9月2日是"奇正转债"最后一个转股日，当日收市前，持有"奇正转 债"的投资者仍可进行转股；2025年9月2日收市后，未转股的"奇正转债"将停 止转股。 1、"奇正转债"赎回价格：101.701元/张（含当期应计利息，当期年利率为 1.80%，且当期利息含税），扣税后的赎回价格以中国证券登记结算有 ...

Core Viewpoint - The letter from the chairman of Qizheng Tibetan Medicine marks the 30th anniversary of the company, highlighting its journey and commitment to the modernization of Tibetan medicine through innovation, inheritance, and integration [1][3]. Group 1: Company Development - Qizheng Tibetan Medicine was established in 1995 and has achieved three significant milestones: being the first company to settle in Tibet for poverty alleviation, listing on the Shenzhen Stock Exchange as the first Tibetan medicine stock, and becoming a leading enterprise in the modernization of Tibetan medicine [1][3]. - The company has maintained a double-digit annual revenue growth over the past 30 years, attributed to its focus on innovation, inheritance, and integration [1][3]. Group 2: Innovation - The company emphasizes the development of effective products, such as pain relief patches and capsules, utilizing modern formulation technologies to enhance stability and convenience [2][4]. - Qizheng has expanded its product range to cover eight therapeutic areas, including respiratory, digestive, cardiovascular, neurological, skin, gynecological, and pediatric treatments [2][4]. Group 3: Inheritance - The company prioritizes the authenticity of its products by establishing connections with contemporary Tibetan medicine masters and supporting the education and development of Tibetan medicine [4]. - Initiatives include the establishment of a traditional Tibetan medicine inheritance center, construction of Tibetan hospitals, and funding for grassroots Tibetan medical clinics [4]. Group 4: Integration - Qizheng promotes Tibetan medicine through evidence-based research, aiming to include its products in national health insurance and essential drug lists, thereby enhancing treatment options for doctors and patients [4]. - The company has developed a comprehensive sales strategy that includes various channels such as tiered medical services, grassroots medical care, retail, B2C, and commercial sales [4].